Floatz logo

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine

Hematopoietic and Lymphoid Cell Neoplasm

City of Hope Medical CentervaccinePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
CYCLOSPORIN A
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine is also rated in:

chronic myeloid leukemiaDormant
B
Indicative ·
58 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
58 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →